Literature DB >> 15172109

Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia.

Riccardo Ientile1, Daniela Caccamo, Maria Concetta Marciano, Monica Currò, Carmen Mannucci, Agata Campisi, Gioacchino Calapai.   

Abstract

Brain injury of the ischemia/reperfusion type induces neuronal damage, mainly by excitatory amino acid release, intracellular Ca(2+) overload and reactive oxygen species production. We have previously demonstrated that glutamate exposure increased transglutaminase activity and transglutaminase 2 expression in cultured cerebellar granule cells and astrocytes. The aim of this study is to evaluate changes in transglutaminase activity and expression using a gerbil model of global cerebral ischemia. Moreover, the distribution and amounts of different transglutaminase isoforms were examined. Transglutaminase activity was measured by incorporation of [(3)H]putrescine into dimethylcasein throughout 48 h of reperfusion following a 3 min occlusion. Compared to sham-operated brains, significant increases were found in the ischemic hippocampus at 24 h of reperfusion, while minor changes were observed in the cortex. RT-PCR demonstrated the presence of significant mRNA amounts of transglutaminase 2 and transglutaminase 1, both in the hippocampus and the cerebral cortex, while low levels were found for transglutaminase 3 transcripts. Interestingly, transglutaminase 2 and transglutaminase 1 mRNAs were 4-fold and 2-fold increased, respectively, in the ischemic hippocampus after 24 h of reperfusion. Western blot analysis of transglutaminase 2 expression confirmed a strong up-regulation in the ischemic hippocampus. However, it is possible to hypothesize that different expression rates of transglutaminase isoforms may be dependent on different responsiveness of their transcription regulatory elements to intracellular calcium overload following excitotoxic cell injury. Our results suggest that increases in transglutaminases may be part of the tissue stress response in global brain ischemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172109     DOI: 10.1016/j.neulet.2004.04.003

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

1.  Transglutaminase 2 protects against ischemic stroke.

Authors:  A J Filiano; J Tucholski; P J Dolan; G Colak; G V W Johnson
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

2.  Subcellular localization patterns of transglutaminase 2 in astrocytes and neurons are differentially altered by hypoxia.

Authors:  Laura Yunes-Medina; Julianne Feola; Gail V W Johnson
Journal:  Neuroreport       Date:  2017-12-13       Impact factor: 1.837

3.  Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury.

Authors:  Julianne Feola; Alan Barton; Abdullah Akbar; Jeffrey Keillor; Gail V W Johnson
Journal:  Brain Res       Date:  2017-05-15       Impact factor: 3.252

Review 4.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

Review 5.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

Review 6.  Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.

Authors:  Kajal Kanchan; Mónika Fuxreiter; László Fésüs
Journal:  Cell Mol Life Sci       Date:  2015-05-06       Impact factor: 9.261

7.  Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia.

Authors:  Gozde Colak; Gail V W Johnson
Journal:  Neurobiol Dis       Date:  2011-12-14       Impact factor: 5.996

8.  Pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1) gene is suppressed by transglutaminase 2 activation.

Authors:  Ayako Miura; Yuki Kambe; Kazuhiko Inoue; Hideki Tatsukawa; Takashi Kurihara; Martin Griffin; Soichi Kojima; Atsuro Miyata
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

9.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.

Authors:  Gary E Gibson; Anatoly Starkov; John P Blass; Rajiv R Ratan; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2009-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.